Four disruptive strategies for removing drug discovery bottlenecks
- 23 October 2012
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 18 (5-6), 265-271
- https://doi.org/10.1016/j.drudis.2012.10.007
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Collaboration versus outsourcing: the need to think outside the boxFuture Medicinal Chemistry, 2011
- Believe it or not: how much can we rely on published data on potential drug targets?Nature Reviews Drug Discovery, 2011
- US academic drug discoveryNature Reviews Drug Discovery, 2011
- Impact of high-throughput screening in biomedical researchNature Reviews Drug Discovery, 2011
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- The Toxicity Data Landscape for Environmental ChemicalsEnvironmental Health Perspectives, 2009
- Clinical attrition due to biased preclinical assessments of potential efficacyPharmacology & Therapeutics, 2007
- Drugs for bad bugs: confronting the challenges of antibacterial discoveryNature Reviews Drug Discovery, 2006
- The ToxCast Program for Prioritizing Toxicity Testing of Environmental ChemicalsToxicological Sciences, 2006
- Failure and Success in Modern Drug Discovery: Guiding Principles in the Establishment of High Probability of Success Drug Discovery OrganizationsMedicinal Chemistry, 2005